LONDON, Feb 1 (Reuters) - AstraZeneca (LSE: AZN.L - news) 's nasal flu vaccine has been approved for use in Europe (news) in children aged from two up to 18 years and is likely to be available for the 2012/13 influenza season, the drugmaker said on Tuesday.
